Long-term lactobacillus ATCC4356 supplementation prevents formation of atherosclerosis via P65-mediated reducing of inflammation and oxidative stress in apoE~(-/-) mice

Lipid-reducing therapies have been widely used for the prevention and treatment on cardiovascular disease. However, common lipid-reducing medications have limited effects and are always accompanied with side effects. Recently, reducing the incidence of cardiovascular disease by the administration of lactobacillus has become a focus but the mechanism remains unclear. In this study, apolipoprotein E-knockout (ApoE-/-) mice fed with different concentrations of Lactobacillus acidophilus ATCC4356 were used to investigate the effects of ATCC4356 on the development of atherogenesis and NF-κB p65-mediated signal pathway. The results showed that ATCC4356 had no impact on weight and blood lipids. However, ATCC4356 effectively relieved atherosclerotic lesions, decreased serum levels of oxidative stress factors (ox-LDL, MDA, SOD) and inflammatory cytokines (TNF-α, IL-10) in ApoE-/mice after being fed with high fat diet. These results suggest that the inhibitory effect of ATCC4356 on the atherosclerotic formation was not dependent on the reduction of cholesterol level but associated with the decreasing inflammatory reactions and oxidative stress effects via suppressing p65-mediated signaling pathway.